問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Veterans General Hospital

List

2394Cases

2017-07-28 - 2018-12-31

Phase II

A multi-center, randomized, double-blind, parallel-group　dose-finding study to assess the effect of 3 doses of　LIK066 compared to placebo or empagliflozin in type 2　diabetes mellitus patients with heart failure

  • Condition/Disease

    type 2　diabetes mellitus patients with heart failure

  • Test Drug

    LIK066

Participate Sites
4Sites

Terminated3Sites

2014-09-01 - 2019-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2015-01-15 - 2023-06-06

Phase III

A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer.

  • Condition/Disease

    hormone receptor positive, HER2-negative, advanced breast cancer.

  • Test Drug

    LEE011

Participate Sites
8Sites

Terminated8Sites

2015-03-13 - 2019-10-24

Phase I/II

A Phase Ib/II study of the ALK inhibitor ceritinib in combination with the CDK4/6 inhibitor LEE011 in patients with ALK-positive non-small cell lung cancer.

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    LEE011, LDK378 (ceritinib)

Participate Sites
3Sites

Terminated3Sites

2015-03-01 - 2018-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2014-11-01 - 2019-05-31

Phase III

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction

  • Condition/Disease

    Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction

  • Test Drug

    LCZ696

Participate Sites
9Sites

Terminated9Sites

2014-12-01 - 2017-09-19

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2017-11-01 - 2019-03-31

Phase II

A Patient and Investigator-blinded, Randomized, Placebo Controlled Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication

  • Condition/Disease

    Peripheral Artery Disease (PAD)

  • Test Drug

    LLG783

Participate Sites
2Sites

Terminated2Sites

2018-02-01 - 2020-05-30

Phase III

A 12-week double-blind, randomized, multi-center study comparing the efficacy and safety of once monthly subcutaneous AMG 334 against placebo in adult episodic migraine patients (EMPOwER)

  • Condition/Disease

    Episodic Migraine

  • Test Drug

    AMG334

Participate Sites
9Sites

Terminated8Sites

Study ended1Sites

林剛旭
China Medical University Hospital

羅榮昇
Linkou Chang Gung Medical Foundation

2018-01-03 - 2021-09-30

Phase III

A Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction

  • Condition/Disease

    Chronic Heart Failure (CHF)

  • Test Drug

    LCZ696

Participate Sites
5Sites

Terminated4Sites

1 206 207 208 209 210 240
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB